+1 347 708 0418
Benign Prostatic Hyperplasia Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Drug Class
Minimally Invasive Surgeries
Laser Therapy
Others
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Company
Abbott
Allergan plc
Astellas Pharma
Asahi Kasei Corporation
Boehringer Ingelheim GmbH
GlaxoSmithKline
Pfizer
Sanofi
Teva Pharmaceutical Industries
Merck
Boston Scientific Corporation
Teleflex Incorporated
Endo International
Urologix
LISA Laser
Olympus
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Drug Class
1.2.3 Minimally Invasive Surgeries
1.2.4 Laser Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Treatment Market Perspective (2017-2028)
2.2 Benign Prostatic Hyperplasia Treatment Growth Trends by Region
2.2.1 Benign Prostatic Hyperplasia Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Benign Prostatic Hyperplasia Treatment Historic Market Size by Region (2017-2022)
2.2.3 Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Region (2023-2028)
2.3 Benign Prostatic Hyperplasia Treatment Market Dynamics
2.3.1 Benign Prostatic Hyperplasia Treatment Industry Trends
2.3.2 Benign Prostatic Hyperplasia Treatment Market Drivers
2.3.3 Benign Prostatic Hyperplasia Treatment Market Challenges
2.3.4 Benign Prostatic Hyperplasia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue (2017-2022)
3.1.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Benign Prostatic Hyperplasia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Treatment Revenue
3.4 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Treatment Revenue in 2021
3.5 Benign Prostatic Hyperplasia Treatment Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Treatment Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Treatment Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Type (2017-2022)
4.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Type (2023-2028)
5 Benign Prostatic Hyperplasia Treatment Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Application (2017-2022)
5.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Benign Prostatic Hyperplasia Treatment Market Size (2017-2028)
6.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Type
6.2.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022)
6.2.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028)
6.2.3 North America Benign Prostatic Hyperplasia Treatment Market Share by Type (2017-2028)
6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Application
6.3.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022)
6.3.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028)
6.3.3 North America Benign Prostatic Hyperplasia Treatment Market Share by Application (2017-2028)
6.4 North America Benign Prostatic Hyperplasia Treatment Market Size by Country
6.4.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022)
6.4.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Treatment Market Size (2017-2028)
7.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type
7.2.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022)
7.2.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028)
7.2.3 Europe Benign Prostatic Hyperplasia Treatment Market Share by Type (2017-2028)
7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application
7.3.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022)
7.3.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028)
7.3.3 Europe Benign Prostatic Hyperplasia Treatment Market Share by Application (2017-2028)
7.4 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country
7.4.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022)
7.4.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size (2017-2028)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type
8.2.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region
8.4.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size (2017-2028)
9.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type
9.2.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Benign Prostatic Hyperplasia Treatment Market Share by Type (2017-2028)
9.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application
9.3.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Benign Prostatic Hyperplasia Treatment Market Share by Application (2017-2028)
9.4 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country
9.4.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (2017-2028)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type
10.2.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country
10.4.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Benign Prostatic Hyperplasia Treatment Introduction
11.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.1.5 Abbott Recent Developments
11.2 Allergan plc
11.2.1 Allergan plc Company Details
11.2.2 Allergan plc Business Overview
11.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Introduction
11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.2.5 Allergan plc Recent Developments
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Details
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.3.5 Astellas Pharma Recent Developments
11.4 Asahi Kasei Corporation
11.4.1 Asahi Kasei Corporation Company Details
11.4.2 Asahi Kasei Corporation Business Overview
11.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Introduction
11.4.4 Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.4.5 Asahi Kasei Corporation Recent Developments
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Details
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.5.5 Boehringer Ingelheim GmbH Recent Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.6.5 GlaxoSmithKline Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Introduction
11.7.4 Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.7.5 Pfizer Recent Developments
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Introduction
11.8.4 Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.8.5 Sanofi Recent Developments
11.9 Teva Pharmaceutical Industries
11.9.1 Teva Pharmaceutical Industries Company Details
11.9.2 Teva Pharmaceutical Industries Business Overview
11.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Introduction
11.9.4 Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.9.5 Teva Pharmaceutical Industries Recent Developments
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Benign Prostatic Hyperplasia Treatment Introduction
11.10.4 Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.10.5 Merck Recent Developments
11.11 Boston Scientific Corporation
11.11.1 Boston Scientific Corporation Company Details
11.11.2 Boston Scientific Corporation Business Overview
11.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Introduction
11.11.4 Boston Scientific Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.11.5 Boston Scientific Corporation Recent Developments
11.12 Teleflex Incorporated
11.12.1 Teleflex Incorporated Company Details
11.12.2 Teleflex Incorporated Business Overview
11.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Introduction
11.12.4 Teleflex Incorporated Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.12.5 Teleflex Incorporated Recent Developments
11.13 Endo International
11.13.1 Endo International Company Details
11.13.2 Endo International Business Overview
11.13.3 Endo International Benign Prostatic Hyperplasia Treatment Introduction
11.13.4 Endo International Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.13.5 Endo International Recent Developments
11.14 Urologix
11.14.1 Urologix Company Details
11.14.2 Urologix Business Overview
11.14.3 Urologix Benign Prostatic Hyperplasia Treatment Introduction
11.14.4 Urologix Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.14.5 Urologix Recent Developments
11.15 LISA Laser
11.15.1 LISA Laser Company Details
11.15.2 LISA Laser Business Overview
11.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Introduction
11.15.4 LISA Laser Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.15.5 LISA Laser Recent Developments
11.16 Olympus
11.16.1 Olympus Company Details
11.16.2 Olympus Business Overview
11.16.3 Olympus Benign Prostatic Hyperplasia Treatment Introduction
11.16.4 Olympus Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
11.16.5 Olympus Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Drug Class
Table 3. Key Players of Minimally Invasive Surgeries
Table 4. Key Players of Laser Therapy
Table 5. Key Players of Others
Table 6. Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Benign Prostatic Hyperplasia Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Benign Prostatic Hyperplasia Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Benign Prostatic Hyperplasia Treatment Market Share by Region (2017-2022)
Table 10. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Benign Prostatic Hyperplasia Treatment Market Share by Region (2023-2028)
Table 12. Benign Prostatic Hyperplasia Treatment Market Trends
Table 13. Benign Prostatic Hyperplasia Treatment Market Drivers
Table 14. Benign Prostatic Hyperplasia Treatment Market Challenges
Table 15. Benign Prostatic Hyperplasia Treatment Market Restraints
Table 16. Global Benign Prostatic Hyperplasia Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Players (2017-2022)
Table 18. Global Top Benign Prostatic Hyperplasia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Treatment as of 2021)
Table 19. Ranking of Global Top Benign Prostatic Hyperplasia Treatment Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Benign Prostatic Hyperplasia Treatment Product Solution and Service
Table 23. Date of Enter into Benign Prostatic Hyperplasia Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2017-2022)
Table 27. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2023-2028)
Table 29. Global Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Application (2017-2022)
Table 31. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Application (2023-2028)
Table 33. North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 34. North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 35. North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 36. North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 37. North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 40. Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 41. Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 42. Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 43. Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 44. Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 45. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 51. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 52. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 53. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 54. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 55. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 56. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 63. Abbott Company Details
Table 64. Abbott Business Overview
Table 65. Abbott Benign Prostatic Hyperplasia Treatment Product
Table 66. Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 67. Abbott Recent Developments
Table 68. Allergan plc Company Details
Table 69. Allergan plc Business Overview
Table 70. Allergan plc Benign Prostatic Hyperplasia Treatment Product
Table 71. Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 72. Allergan plc Recent Developments
Table 73. Astellas Pharma Company Details
Table 74. Astellas Pharma Business Overview
Table 75. Astellas Pharma Benign Prostatic Hyperplasia Treatment Product
Table 76. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 77. Astellas Pharma Recent Developments
Table 78. Asahi Kasei Corporation Company Details
Table 79. Asahi Kasei Corporation Business Overview
Table 80. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product
Table 81. Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 82. Asahi Kasei Corporation Recent Developments
Table 83. Boehringer Ingelheim GmbH Company Details
Table 84. Boehringer Ingelheim GmbH Business Overview
Table 85. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product
Table 86. Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 87. Boehringer Ingelheim GmbH Recent Developments
Table 88. GlaxoSmithKline Company Details
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product
Table 91. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 92. GlaxoSmithKline Recent Developments
Table 93. Pfizer Company Details
Table 94. Pfizer Business Overview
Table 95. Pfizer Benign Prostatic Hyperplasia Treatment Product
Table 96. Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 97. Pfizer Recent Developments
Table 98. Sanofi Company Details
Table 99. Sanofi Business Overview
Table 100. Sanofi Benign Prostatic Hyperplasia Treatment Product
Table 101. Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 102. Sanofi Recent Developments
Table 103. Teva Pharmaceutical Industries Company Details
Table 104. Teva Pharmaceutical Industries Business Overview
Table 105. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product
Table 106. Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 107. Teva Pharmaceutical Industries Recent Developments
Table 108. Merck Company Details
Table 109. Merck Business Overview
Table 110. Merck Benign Prostatic Hyperplasia Treatment Product
Table 111. Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 112. Merck Recent Developments
Table 113. Boston Scientific Corporation Company Details
Table 114. Boston Scientific Corporation Business Overview
Table 115. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product
Table 116. Boston Scientific Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 117. Boston Scientific Corporation Recent Developments
Table 118. Teleflex Incorporated Company Details
Table 119. Teleflex Incorporated Business Overview
Table 120. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product
Table 121. Teleflex Incorporated Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 122. Teleflex Incorporated Recent Developments
Table 123. Endo International Company Details
Table 124. Endo International Business Overview
Table 125. Endo International Benign Prostatic Hyperplasia Treatment Product
Table 126. Endo International Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 127. Endo International Recent Developments
Table 128. Urologix Company Details
Table 129. Urologix Business Overview
Table 130. Urologix Benign Prostatic Hyperplasia Treatment Product
Table 131. Urologix Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 132. Urologix Recent Developments
Table 133. LISA Laser Company Details
Table 134. LISA Laser Business Overview
Table 135. LISA Laser Benign Prostatic Hyperplasia Treatment Product
Table 136. LISA Laser Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 137. LISA Laser Recent Developments
Table 138. Olympus Company Details
Table 139. Olympus Business Overview
Table 140. Olympus Benign Prostatic Hyperplasia Treatment Product
Table 141. Olympus Revenue in Benign Prostatic Hyperplasia Treatment Business (2017-2022) & (US$ Million)
Table 142. Olympus Recent Developments
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostatic Hyperplasia Treatment Market Share by Type: 2021 VS 2028
Figure 2. Drug Class Features
Figure 3. Minimally Invasive Surgeries Features
Figure 4. Laser Therapy Features
Figure 5. Others Features
Figure 6. Global Benign Prostatic Hyperplasia Treatment Market Share by Application: 2021 VS 2028
Figure 7. Hospitals Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Specialty Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Benign Prostatic Hyperplasia Treatment Report Years Considered
Figure 12. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Benign Prostatic Hyperplasia Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Benign Prostatic Hyperplasia Treatment Market Share by Region: 2021 VS 2028
Figure 15. Global Benign Prostatic Hyperplasia Treatment Market Share by Players in 2021
Figure 16. Global Top Benign Prostatic Hyperplasia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Treatment as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Treatment Revenue in 2021
Figure 18. North America Benign Prostatic Hyperplasia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Benign Prostatic Hyperplasia Treatment Market Size Market Share by Type (2017-2028)
Figure 20. North America Benign Prostatic Hyperplasia Treatment Market Size Market Share by Application (2017-2028)
Figure 21. North America Benign Prostatic Hyperplasia Treatment Market Size Share by Country (2017-2028)
Figure 22. United States Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Benign Prostatic Hyperplasia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Benign Prostatic Hyperplasia Treatment Market Size Market Share by Type (2017-2028)
Figure 26. Europe Benign Prostatic Hyperplasia Treatment Market Size Market Share by Application (2017-2028)
Figure 27. Europe Benign Prostatic Hyperplasia Treatment Market Size Share by Country (2017-2028)
Figure 28. Germany Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size Share by Region (2017-2028)
Figure 38. China Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Latin America Benign Prostatic Hyperplasia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Benign Prostatic Hyperplasia Treatment Market Size Market Share by Type (2017-2028)
Figure 46. Latin America Benign Prostatic Hyperplasia Treatment Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Benign Prostatic Hyperplasia Treatment Market Size Share by Country (2017-2028)
Figure 48. Mexico Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size Share by Country (2017-2028)
Figure 54. Turkey Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Abbott Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 58. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 59. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 60. Asahi Kasei Corporation Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 61. Boehringer Ingelheim GmbH Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 63. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 64. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 65. Teva Pharmaceutical Industries Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 66. Merck Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 67. Boston Scientific Corporation Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 68. Teleflex Incorporated Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 69. Endo International Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 70. Urologix Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 71. LISA Laser Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 72. Olympus Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2017-2022)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Buy
